|  | Medical visits | ARV visits | ||
---|---|---|---|---|---|
Variable |  | Crude RR (95% CI) | Adjusted RR †(95% CI) | Crude RR (95% CI) | Adjusted RR †(95% CI) |
Sex | Female | Reference | Reference | Reference | Reference |
 | Male | 1.15 (1.05-1.27) | 1.16 (1.05-1.28) | 1.14 (1.03-1.28) | 1.15 (1.02-1.28) |
Baseline BMI | ≥17.5 | Reference | Reference | Reference | Reference |
 | < 17.5 | 1.11 (1.00-1.24) | 1.09 (0.97-1.22) | 1.24 (1.09-1.40) | 1.22 (1.08-1.39) |
Age at ART initiation | ≥ 50 | Reference | Reference | Reference | Reference |
 | 40-49.9 | 1.11 (0.92-1.35) | 1.15 (0.94-1.40) | 1.00 (0.80-1.25) | 1.00 (0.80-1.26) |
 | 30-39.9 | 1.04 (0.87-1.25) | 1.07 (0.89-1.30) | 1.08 (0.88-1.33) | 1.08 (0.87-1.33) |
 | 25-29.9 | 1.07 (0.87-1.32) | 1.10 (0.89-1.37) | 1.01 (0.80-1.29) | 1.03 (0.81-1.32) |
 | 18-24.9 | 1.10 (0.83-1.45) | 1.13 (0.86-1.51) | 1.22 (0.91-1.65) | 1.23 (0.90-1.67) |
Baseline CD4 count (cells/mm3) | 100-200 | Reference | Reference | Reference | Reference |
 | 51-100 | 0.89 (0.78-1.01) | 0.88 (0.77-1.00) | 0.93 (0.81-1.08) | 0.95 (0.83-1.07) |
 | 0-50 vs. | 1.00 (0.90-1.12) | 0.98 (0.88-1.09) | 0.99 (0.88-1.12) | 0.93 (0.80-1.07) |
Baseline Hb (ug/dL) | ≥ 10.0 | Reference | Reference | Reference | Reference |
 | < 10.0 | 1.01 (0.91-1.13) | 1.02 (0.92-1.14) | 1.00 (0.89-1.14) | 1.00 (0.88-1.13) |
Baseline WHO stage | I/II | Reference | Reference | Reference | Reference |
 | III/IV | 1.04 (0.94-1.14) | 1.03 (0.93-1.14) | 1.06 (0.95-1.19) | 1.03 (0.92-1.16) |
Baseline NRTI | d4T | Reference | Reference | Reference | Reference |
 | AZT | 1.13 (0.86-1.48) | 1.10 (0.84-1.44) | 0.99 (0.71-1.39) | 0.98 (0.70-1.38) |
Baseline NNRTI | EFV | Reference | Reference | Reference | Reference |
 | NVP | 1.13 (0.96-1.33) | 1.18 (1.00-1.40) | 1.04 (0.85-1.26) | 1.05 (0.86-1.29) |